Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
<Group xmlns="http://hl7.org/fhir">
<id value="264323"/>
<meta>
<versionId value="16"/>
<lastUpdated value="2024-08-01T12:27:35.568Z"/>
<profile
value="http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-eligibility-criteria"/>
</meta>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml">[No data.]</div>
</text>
<extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
<valueContactDetail>
<name value="Sheyu Li"/>
</valueContactDetail>
</extension>
<extension
url="http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact">
<valueRelatedArtifact>
<type value="cite-as"/>
<citation
value="Eligibility criteria for NMA_Diabetes [Database Entry: FHIR Group Resource]. Contributors: Sheyu Li [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 264323. Revised 2024-07-30. Available at: https://fevir.net/resources/Group/264323. Computable resource at: https://fevir.net/resources/Group/264323."/>
</valueRelatedArtifact>
</extension>
<extension url="http://hl7.org/fhir/StructureDefinition/artifact-title">
<valueString value="Eligibility criteria for NMA_Diabetes"/>
</extension>
<extension url="http://hl7.org/fhir/StructureDefinition/artifact-url">
<valueUri value="https://fevir.net/resources/Group/264323"/>
</extension>
<extension
url="http://hl7.org/fhir/StructureDefinition/artifact-publisher">
<valueString value="Computable Publishing LLC"/>
</extension>
<extension
url="http://hl7.org/fhir/StructureDefinition/artifact-copyright">
<valueMarkdown
value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
</extension>
<extension url="http://hl7.org/fhir/StructureDefinition/artifact-contact">
<valueContactDetail>
<telecom>
<system value="email"/>
<value value="support@computablepublishing.com"/>
</telecom>
</valueContactDetail>
</extension>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/combination-method">
<valueCode value="all-of"/>
</extension>
<modifierExtension
url="http://hl7.org/fhir/StructureDefinition/artifact-status">
<valueCode value="active"/>
</modifierExtension>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="ACSN"/>
<display value="Accession ID"/>
</coding>
<text value="FEvIR Object Identifier"/>
</type>
<system value="https://fevir.net"/>
<value value="264323"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<description
value="Eligible randomised controlled trials compared drugs used to treat adults with type 2 diabetes. We considered the following drug classes: SGLT-2 inhibitors, GLP-1 receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinediones, sulfonylureas, metformin, α-glucosidase inhibitors, meglitinides, insulins, dual GIP/GLP-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists. Appendix 1.3 describes the detailed drug names and definitions of control arms (typically standard treatment at the time the trials were conducted, representing the treatment regimens the patient received before the clinician considered adding a new drug). Eligible trials had a follow-up of 24 weeks or longer. Trials systematically comparing combinations of more than one drug treatment class with no drug treatment, subgroup analyses of randomised controlled trials, and non-English language studies were deemed ineligible."/>
<type value="animal"/>
<membership value="definitional"/>
<code>
<text value="Research study"/>
</code>
<characteristic>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description">
<valueMarkdown
value="The study design is a randomised controlled trial."/>
</extension>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/181513"/>
<code value="SEVCO:01000"/>
<display value="Study Design"/>
</coding>
<text value="Study design"/>
</code>
<valueCodeableConcept>
<coding>
<system value="http://hl7.org/fhir/study-design"/>
<code value="SEVCO:01003"/>
<display value="randomized assignment"/>
</coding>
</valueCodeableConcept>
<exclude value="false"/>
</characteristic>
<characteristic>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description">
<valueMarkdown
value="All the participants are adults with type 2 diabetes."/>
</extension>
<code>
<text value="Study population"/>
</code>
<valueReference>🔗
<reference value="Group/265093"/>
<type value="Group"/>
<display value="Adults with type 2 diabetes"/>
</valueReference>
<exclude value="false"/>
</characteristic>
<characteristic>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description">
<valueMarkdown
value="The medication class should be among one or more of SGLT-2 inhibitors, GLP-1 receptr agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinediones, sulfonylureas, metformin, α-glucosidase inhibitors, meglitinides, insulins, dual GIP/GLP-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists."/>
</extension>
<code>
<text value="Study interventions"/>
</code>
<valueReference>🔗
<reference value="Group/265092"/>
<type value="Group"/>
<display value="Diabetes treatment medication"/>
</valueReference>
<exclude value="false"/>
</characteristic>
<characteristic>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description">
<valueMarkdown
value="Eligible trials had a follow-up of 24 weeks or longer."/>
</extension>
<code>
<text value="Duration of follow up"/>
</code>
<valueQuantity>
<value value="24"/>
<comparator value=">="/>
<unit value="weeks"/>
<system value="http://unitsofmeasure.org"/>
<code value="wk"/>
</valueQuantity>
<exclude value="false"/>
</characteristic>
<characteristic>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description">
<valueMarkdown
value="We excluded non-English language published studies."/>
</extension>
<code>
<text value="Language of publication"/>
</code>
<valueCodeableConcept>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="English"/>
</coding>
</valueCodeableConcept>
<exclude value="false"/>
</characteristic>
<characteristic>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description">
<valueMarkdown
value="We excluded trials systematically comparing combinations of more than one drug treatment class with no drug treatment."/>
</extension>
<code>
<text value="Defined by CodeableConcept"/>
</code>
<valueCodeableConcept>
<text
value="Systematically comparing combinations of more than one drug treatment class with no drug treatment"/>
</valueCodeableConcept>
<exclude value="true"/>
</characteristic>
<characteristic>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description">
<valueMarkdown
value="We excluded subgroup analyses of randomised controlled trials."/>
</extension>
<code>
<text value="Defined by CodeableConcept"/>
</code>
<valueCodeableConcept>
<text value="Subgroup analyses"/>
</valueCodeableConcept>
<exclude value="true"/>
</characteristic>
</Group>
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#2.0.0-ballot based on FHIR 6.0.0-ballot2. Generated 2024-11-01
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change